Lisa M. Schwartz
Research Subjects
Lisa M. Schwartz has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Steven Woloshin
Center for Medicine in the Media, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA
12 shared publications- Steven Woloshin
Veterans Affairs Outcomes Group, White River Junction, Vermont, USA
12 shared publications Barnett S. Kramer
Affiliations of authors: Center for Medicine and the Media, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH (LMS, SW); VA Outcomes Group (111B), VA Medical Center, VT (LMS, SW); Office of Disease Prevention, National Institutes of Health, Bethesda, MD (BSK)
3 shared publicationsH. Gilbert Welch
Affiliations of authors: The Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT; Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH; and Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH
3 shared publications- H. Gilbert Welch
Center for Surgery and Public Health, Brigham and Women’s Hospital, Boston, Massachusetts
2 shared publications Abigail T. Kennedy
From the Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont, and The Dartmouth Institute for Health Policy and Clinical Practice and Dartmouth Medical School, Hanover, New Hampshire
1 shared publication
Latest Publications
- Open Access
- 14 September 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (18) , 9688
Validation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014–2016
The purpose of this study is to validate the seven-item wheezing module from the International Study of Asthma and Allergies in Children (ISAAC) in the nationally representative Population Assessment of Tobacco and Health Study. Adult participants with complete Wave 2–3 data were selected, including those with asthma but excluding those with COPD and other respiratory diseases (n = 16,295). We created a nine-point respiratory symptom index from the ISAAC questions, assessed the reliability of the index, and examined associations with self-reported asthma diagnosis. Threshold values were assessed for association with functional outcomes. The weighted prevalence for one or more respiratory symptom was 18.0% (SE = 0.5) for adults without asthma, 70.1% (SE = 1.3) for those with lifetime asthma, 75.7% (SE = 3.7) for adults with past-year asthma not on medications, and 92.6% (SE = 1.6) for those on medications. Cronbach’s alpha for the respiratory symptom index was 0.86. Index scores of ≥2 or ≥3 yielded functionally important respiratory symptom prevalence of 7–10%, adequate sensitivity and specificity for identifying asthma, and consistent independent associations with all functional outcomes and tobacco use variables. Respiratory symptom index scores of ≥2 or ≥3 are indicative of functionally important respiratory symptoms and could be used to assess the relationship between tobacco use and respiratory health.
- 14 September 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (18) , 9688
Open AccessValidation of an Index for Functionally Important Respiratory Symptoms among Adults in the Nationally Representative Population Assessment of Tobacco and Health Study, 2014–2016
The purpose of this study is to validate the seven-item wheezing module from the International Study of Asthma and Allergies in Children (ISAAC) in the nationally representative Population Assessment of Tobacco and Health Study. Adult participants with complete Wave 2–3 data were selected, including those with asthma but excluding those with COPD and other respiratory diseases (n = 16,295). We created a nine-point respiratory symptom index from the ISAAC questions, assessed the reliability of the index, and examined associations with self-reported asthma diagnosis. Threshold values were assessed for association with functional outcomes. The weighted prevalence for one or more respiratory symptom was 18.0% (SE = 0.5) for adults without asthma, 70.1% (SE = 1.3) for those with lifetime asthma, 75.7% (SE = 3.7) for adults with past-year asthma not on medications, and 92.6% (SE = 1.6) for those on medications. Cronbach’s alpha for the respiratory symptom index was 0.86. Index scores of ≥2 or ≥3 yielded functionally important respiratory symptom prevalence of 7–10%, adequate sensitivity and specificity for identifying asthma, and consistent independent associations with all functional outcomes and tobacco use variables. Respiratory symptom index scores of ≥2 or ≥3 are indicative of functionally important respiratory symptoms and could be used to assess the relationship between tobacco use and respiratory health.
Overcoming overuse: the way forward is not standing still-an essay by Steven Woloshin and Lisa M Schwartz
Overdiagnosis and overtreatment are real, wasteful, and harmful, and doctors have an ethical duty to act, say Steven Woloshin and Lisa M Schwartz, responding to recent claims otherwise in the New England Medical Journal
Overcoming overuse: the way forward is not standing still-an essay by Steven Woloshin and Lisa M Schwartz
Overdiagnosis and overtreatment are real, wasteful, and harmful, and doctors have an ethical duty to act, say Steven Woloshin and Lisa M Schwartz, responding to recent claims otherwise in the New England Medical Journal
- Open Access
- 23 January 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (4) , 404-406
Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications
Publication of interim results of randomized trials can be consequential, potentially undermining trial integrity by unblinding or encouraging dropouts and crossovers,1 introducing uncertainty because results based on fewer outcomes are less precise, or overstating true treatment effects as demonstrated primarily in trials terminated early2,3 but also in ongoing trials.4 Nevertheless, because interim results are new and often promising, they may generate substantial interest, which can be misleading if results change. We describe the characteristics of interim publications from ongoing randomized trials and compare their consistency and prominence with those of final publications.
- 23 January 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (4) , 404-406
Open AccessCharacteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications
Publication of interim results of randomized trials can be consequential, potentially undermining trial integrity by unblinding or encouraging dropouts and crossovers,1 introducing uncertainty because results based on fewer outcomes are less precise, or overstating true treatment effects as demonstrated primarily in trials terminated early2,3 but also in ongoing trials.4 Nevertheless, because interim results are new and often promising, they may generate substantial interest, which can be misleading if results change. We describe the characteristics of interim publications from ongoing randomized trials and compare their consistency and prominence with those of final publications.
- 11 September 2015
- Published by National Academy of Medicine in NAM Perspectives
- Vol. 5 (9)
FDA and the Media: Lessons from Tysabri about Communicating Uncertainty
- 11 September 2015
- Published by National Academy of Medicine in NAM Perspectives
- Vol. 5 (9)
FDA and the Media: Lessons from Tysabri about Communicating Uncertainty
- Open Access
- 26 November 2014
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (20) , 2163-2165
US Food and Drug Administration and Design of Drug Approval Studies
To enhance protocol quality, federal regulations encourage but do not require meetings between pharmaceutical companies and the US Food and Drug Administration
- 26 November 2014
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (20) , 2163-2165
Open AccessUS Food and Drug Administration and Design of Drug Approval Studies
To enhance protocol quality, federal regulations encourage but do not require meetings between pharmaceutical companies and the US Food and Drug Administration
- Open Access
- 13 August 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (supplement) , 14069-14074
The Drug Facts Box: Improving the communication of prescription drug information
Communication about prescription drugs ought to be a paragon of public science communication. Unfortunately, it is not. Consumers see $4 billion of direct-to-consumer advertising annually, which typically fails to present data about how well drugs work. The professional label—the Food and Drug Administration's (FDA) mechanism to get physicians information needed for appropriate prescribing—may also fail to present benefit data. FDA labeling guidance, in fact, suggests that industry omit benefit data for new drugs in an existing class and for drugs approved on the basis of unfamiliar outcomes (such as depression rating scales). The medical literature is also problematic: there is selective reporting of favorable trials, favorable outcomes within trials, and “spinning” unfavorable results to maximize benefit and minimize harm. In contrast, publicly available FDA reviews always include the phase 3 trial data on benefit and harm, which are the basis of drug approval. However, these reviews are practically inaccessible: lengthy, poorly organized, and weakly summarized. To improve accessibility, we developed the Drug Facts Box: a one-page summary of benefit and harm data for each indication of a drug. A series of studies—including national randomized trials—demonstrates that most consumers understand the Drug Facts Box and that it improves decision-making. Despite calls from their own Risk Communication Advisory Committee and Congress (in the Affordable Care Act) to consider implementing boxes, the FDA announced it needs at least 3–5 y more to make a decision. Given its potential public health impact, physicians and the public should not have to wait that long for better drug information.
- 13 August 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (supplement) , 14069-14074
Open AccessThe Drug Facts Box: Improving the communication of prescription drug information
Communication about prescription drugs ought to be a paragon of public science communication. Unfortunately, it is not. Consumers see $4 billion of direct-to-consumer advertising annually, which typically fails to present data about how well drugs work. The professional label—the Food and Drug Administration's (FDA) mechanism to get physicians information needed for appropriate prescribing—may also fail to present benefit data. FDA labeling guidance, in fact, suggests that industry omit benefit data for new drugs in an existing class and for drugs approved on the basis of unfamiliar outcomes (such as depression rating scales). The medical literature is also problematic: there is selective reporting of favorable trials, favorable outcomes within trials, and “spinning” unfavorable results to maximize benefit and minimize harm. In contrast, publicly available FDA reviews always include the phase 3 trial data on benefit and harm, which are the basis of drug approval. However, these reviews are practically inaccessible: lengthy, poorly organized, and weakly summarized. To improve accessibility, we developed the Drug Facts Box: a one-page summary of benefit and harm data for each indication of a drug. A series of studies—including national randomized trials—demonstrates that most consumers understand the Drug Facts Box and that it improves decision-making. Despite calls from their own Risk Communication Advisory Committee and Congress (in the Affordable Care Act) to consider implementing boxes, the FDA announced it needs at least 3–5 y more to make a decision. Given its potential public health impact, physicians and the public should not have to wait that long for better drug information.
- Open Access
- 12 December 2011
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (24) , 1903
Response: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right
Dr Pharoah may be right that there is no user-friendly definition for the P value. But that does not mean there cannot be one. And there needs to be one because medical journals report P values all the time. A user-friendly definition is crucial to help doctors, patients, and journalists understand the results of research.
- 12 December 2011
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (24) , 1903
Open AccessResponse: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right
Dr Pharoah may be right that there is no user-friendly definition for the P value. But that does not mean there cannot be one. And there needs to be one because medical journals report P values all the time. A user-friendly definition is crucial to help doctors, patients, and journalists understand the results of research.
- 28 November 2011
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 171 (21) , 1963-1964
Caution on Interpreting the Time Trends in Pulmonary Embolism as “Overdiagnosis”—Reply
In reply We thank Ashrani and Heit for their interest in our study.1 Because direct evidence of overdiagnosis can only be obtained if individuals diagnosed as having a PE are observed without treating the PE until they die from other causes, using indirect evidence from population data is an established method of identifying overdiagnosis.2-4 The pattern of rising incidence, stable mortality, and decreasing case fatality in the setting of the introduction of a highly sensitive test is strongly suggestive of overdiagnosis.5 While we agree with Ashrani and Heit about the general limitations inherent in administrative data (and noted many of these limitations in our article), we are not convinced by their specific comments about competing explanations for our findings.
- 28 November 2011
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 171 (21) , 1963-1964
Caution on Interpreting the Time Trends in Pulmonary Embolism as “Overdiagnosis”—Reply
In reply We thank Ashrani and Heit for their interest in our study.1 Because direct evidence of overdiagnosis can only be obtained if individuals diagnosed as having a PE are observed without treating the PE until they die from other causes, using indirect evidence from population data is an established method of identifying overdiagnosis.2-4 The pattern of rising incidence, stable mortality, and decreasing case fatality in the setting of the introduction of a highly sensitive test is strongly suggestive of overdiagnosis.5 While we agree with Ashrani and Heit about the general limitations inherent in administrative data (and noted many of these limitations in our article), we are not convinced by their specific comments about competing explanations for our findings.
- 28 March 2011
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 171 (6) , 489-490
Not So Silver Lining
- 28 March 2011
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 171 (6) , 489-490
Not So Silver Lining
- Open Access
- 26 April 2010
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 102 (11) , 830
Response: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right
Dr Lash and colleagues raise some important issues that we would like to clarify. First, like most journals, the Journal does not submit certain categories of published content to formal peer review, including news articles, invited editorials, editor's notes (and Correspondence, for that matter). This is to maintain a timely and free-flowing exchange of opinions and comment on the published literature. Such content is clearly identified and distinguishable from the peer-reviewed primary medical studies.
- 26 April 2010
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 102 (11) , 830
Open AccessResponse: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right
Dr Lash and colleagues raise some important issues that we would like to clarify. First, like most journals, the Journal does not submit certain categories of published content to formal peer review, including news articles, invited editorials, editor's notes (and Correspondence, for that matter). This is to maintain a timely and free-flowing exchange of opinions and comment on the published literature. Such content is clearly identified and distinguishable from the peer-reviewed primary medical studies.